checking sources…P2 · Buy-side

Loading…

GSK plc (GSK)

Completion date history

Slipped 23 times (13 pull-ins also on record) — 6601 cumulative days slipped

2029-06-21→2029-06-22(+1d)
2026-09-01→2026-09-10(+9d)
2026-07-13→2028-02-14(+581d)
2026-10-21→2027-07-29(+281d)
2027-05-05→2027-05-17(+12d)
2029-12-19→2029-12-05(-14d)
2027-01-29→2027-01-28(-1d)
2026-05-25→2027-05-14(+354d)
2026-01-31→2027-01-31(+365d)
2027-11-18→2027-11-05(-13d)
2026-11-24→2026-11-17(-7d)
2029-08-21→2028-12-13(-251d)
2028-04-19→2028-04-10(-9d)
2029-08-20→2028-12-13(-250d)
2026-09-22→2027-05-20(+240d)
2023-07-17→2023-07-19(+2d)
2027-03-31→2027-06-14(+75d)
2024-06-07→2026-06-22(+745d)
2027-11-24→2027-10-29(-26d)
2026-06-30→2027-08-30(+426d)
2029-04→2029-06(+61d)
2029-12-17→2030-07-22(+217d)
2027-07-29→2026-07-29(-365d)
2028-01-10→2029-01-09(+365d)
2027-08-31→2026-06-30(-427d)
2027-01-01→2028-06-01(+517d)
2026-07-01→2026-06-19(-12d)
2029-05-04→2029-05-02(-2d)
2025-06-01→2027-06-01(+730d)
2029-07-17→2029-07-30(+13d)
2026-12-11→2028-12-29(+749d)
2026-12-09→2026-11-19(-20d)
2028-07-31→2029-03-21(+233d)
2025-11-30→2026-11-30(+365d)
2029-09-24→2030-01-10(+108d)
2026-07-15→2026-12-14(+152d)

Timeline — every real change on record

FDA3/28/1949, 5:30:00 AM
FDA approval
FDA9/24/1954, 5:30:00 AM
FDA approval
FDA10/23/1956, 5:30:00 AM
FDA approval
FDA1/25/1957, 5:30:00 AM
FDA approval
FDA4/8/1957, 5:30:00 AM
FDA approval
FDA6/5/1957, 5:30:00 AM
FDA approval
FDA9/18/1957, 5:30:00 AM
FDA approval

Relationships — real graph edges

SPONSORS→ Trial_990f7d36740f4d22922795fd36b53a91
SPONSORS→ Trial_7359d5dcd2514cba8bc6768e29f33d00
SPONSORS→ Trial_acf44c81bd2f4bc6905e6a81ef5a5308
SPONSORS→ Trial_f4ff0a7749ce4c88b344313e4265945c
SPONSORS→ Trial_ac3a3df846e34959b4d9a9e027e052f7
SPONSORS→ Trial_9dcdf6d2ae2248fb8e71f83c0366ff4d
SPONSORS→ Trial_4f2eb4e8a8fe4f4abbb7a921f7119f43
SPONSORS→ Trial_d379da08cdd545018ba6808e52222c08
SPONSORS→ Trial_139ed92f2b374ef4bddaf073fb786069
SPONSORS→ Trial_4812d4cf4c1d44399cf8092034bd5a03
SPONSORS→ Trial_0fec7ca7fe0b4b94a953e38ef97de65e
SPONSORS→ Trial_a95898b9525448ddb9a450ee91834647
SPONSORS→ Trial_8eab1fe1ba6b48beb587e57c414ea7b6
SPONSORS→ Trial_9b242bfc082348fdbe58d8336673d9cf

Evidence — source documents

CTGOV9/22/2026, 5:04:53 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD. * If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia. * Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week. * Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). Exclusion Criteria: * Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia. * Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD. * Females who are pregnant or breastfeeding, or planning to conceive within the study period. * Any experimental vaccine or gene therapy. * History of cancer within the last 5 years. * Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban). * Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.

→

Inclusion Criteria: * Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD. * If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia. * Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week. * Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). Exclusion Criteria: * Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia. * Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. * Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD. * Females who are pregnant or breastfeeding, or planning to conceive within the study period. * Any experimental vaccine or gene therapy. * History of cancer, unless in remission or stable/adequately controlled. * Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban). * Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.

CTGOV9/23/2026, 5:06:01 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Male or female aged 18 to 80 years inclusive, at the time of signing the Informed consent form (ICF). * Diagnosis of IBS-D or IBS-M according to the Rome IV criteria at screening * Moderate or severe irritable bowel syndrome (IBS) based on Irritable bowel syndrome Severity Scoring System (IBS SSS) at screening visit * Weekly API score \>=4.0 in each week of the run-in period * IBS-D: at least one stool with BSFS Type 6 or 7 consistency on at least 2 days in each week of the run-in period * IBS-M: an average of 2 days per week with abnormal bowel movements (BSFS Type 1, 2, 6, or 7) during the run-in period, and greater than (\>)25% of abnormal bowel movements must be Type 6 or 7 and \>25% Type 1 or 2 Exclusion Criteria: * Diagnosis of Irritable bowel syndrome - constipation (IBS-C) or Irritable bowel syndrome - unclassified (IBS-U) * History or presence of inflammatory or immune-mediated Gastrointestinal (GI) disorders e.g. inflammatory bowel disease, microscopic colitis, or celiac disease * History or presence of GI infection (confirmed with stool culture) within 3 months prior to screening * History or presence of bile salt diarrhea * History of a primary psychiatric diagnosis that the Investigator considers may interfere with study assessments (e.g., schizophrenia, schizoaffective disorder, major depression, anxiety, panic attacks or bipolar disorder) OR Hospital Anxiety and Depression Scale (HADS) score of \>10 at screening. * Prior use of more than two of the following therapies or classes of therapy for the management of IBS: * Antidepressants or neuromodulators (e.g., Tricyclic antidepressant \[TCAs\], Selective serotonin reuptake inhibitor \[SSRIs\], gabapentinoids) * Antibiotics (e.g., rifaximin, neomycin) * 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (e.g., alosetron, ramosetron, ondansetron) * Mu-opioid receptor agonists (e.g., eluxadoline) * Secretagogues (e.g., linaclotide, lubiprostone, plecanatide, tenapanor) * 5-hydroxytryptamine 4 (5-HT4) receptor agonists (e.g., tegaserod) * Abnormal thyroid function tests less than (\<) Lower limit of normal (LLN) or greater than (\>) upper limit of normal (ULN) confirmed at screening with Thyroid stimulating hormone (TSH) * Positive celiac serology * Elevated fecal calprotectin levels * QT interval corrected using Fridericia's formula (QTcF) \>450 millisecond (msec) or QTcF \>480 msec for participants with bundle branch block using the Fridericia's corrected QT interval. * Clinically significant abnormal laboratory tests at screening, after one repeat laboratory test if allowed by the Medical Monitor, including the following: * Alanine aminotransferase (ALT) \>2\*ULN * Total Bilirubin \>1.5\*ULN * Aspartate aminotransferase (AST) \>2\*ULN * Current or chronic history of liver disease (Child-Pugh class A, B, or C) or biliary abnormalities (with the exception of asymptomatic gallstones). Participants with known or suspected Gilbert's Syndrome are not permissible.

→

Inclusion Criteria: * Male or female aged 18 to 80 years inclusive, at the time of signing the Informed consent form (ICF). * Diagnosis of IBS-D or IBS-M according to the Rome IV V criteria at screening with documented IBS symptoms onset at least 6 months prior to the diagnosis * Moderate or severe irritable bowel syndrome (IBS) based on Irritable bowel syndrome Severity Scoring System (IBS SSS) at screening visit * Weekly API score \>=4.0 in each week of the run-in period * IBS-D: at least one stool with BSFS Type 6 or 7 consistency on at least 2 days in each week of the run-in period * IBS-M: an average of at least 2 days per week with abnormal bowel movements (BSFS Type 1, 2, 6, or 7) during the run-in period, and greater than (\>)25% of abnormal bowel movements must be Type 6 or 7 and \>25% Type 1 or 2 Exclusion Criteria: * Diagnosis of Irritable bowel syndrome - constipation (IBS-C) or Irritable bowel syndrome - unclassified (IBS-U) * History or presence of inflammatory or immune-mediated disorders of the small or large intestine e.g. inflammatory bowel disease, microscopic colitis, or celiac disease * History or presence of GI infection (confirmed with stool culture) within 3 months prior to screening * History or presence of small intestinal bacterial overgrowth within 6 months prior to screening * History or presence of bile salt diarrhea * History of a primary psychiatric diagnosis that the Investigator considers may interfere with study assessments (e.g., schizophrenia, schizoaffective disorder, major depression, anxiety, panic attacks or bipolar disorder) OR Hospital Anxiety and Depression Scale (HADS) score of \>10 on either the anxiety or depression sub-scale at screening. * Prior use of more than two of the following therapies or classes of therapy for the management of IBS: * Antidepressants or neuromodulators (e.g., Tricyclic antidepressant \[TCAs\], Selective serotonin reuptake inhibitor \[SSRIs\], gabapentinoids) * Antibiotics (e.g., rifaximin, neomycin) * 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (e.g., alosetron, ramosetron, ondansetron) * Mu-opioid receptor agonists (e.g., eluxadoline) * Secretagogues (e.g., linaclotide, lubiprostone, plecanatide, tenapanor) * 5-hydroxytryptamine 4 (5-HT4) receptor agonists (e.g., tegaserod) * Abnormal thyroid function tests less than (\<) Lower limit of normal (LLN) or greater than (\>) upper limit of normal (ULN) confirmed at screening with Thyroid stimulating hormone (TSH) * Positive celiac serology * Elevated fecal calprotectin levels * QT interval corrected using Fridericia's formula (QTcF) \>450 millisecond (msec) or QTcF \>480 msec for participants with bundle branch block using the Fridericia's corrected QT interval (performed during Run-in period considered as screening ECG). * Clinically significant abnormal laboratory tests at screening, after one repeat laboratory test if allowed by the Medical Monitor, including the following: * Alanine aminotransferase (ALT) \>2\*ULN * Total Bilirubin \>1.5\*ULN * Aspartate aminotransferase (AST) \>2\*ULN * Current or chronic history of liver disease (Child-Pugh class A, B, or C) or biliary abnormalities (with the exception of asymptomatic gallstones). Participants with known or suspected Gilbert's Syndrome are not permissible.

CTGOV9/26/2026, 5:09:29 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Is at least 18 years of age or the legal age of consent * Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory to standard therapy, for which no standard treatment is available, or who is intolerant to established standard of care therapies. * Has documented disease progression based on radiologic imaging, during or after most recent line of treatment. * Has at least one target lesion per RECIST 1.1 (participants in Part 1a backfill and Part 1b). * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 and no deterioration in the 2 weeks before enrollment. * Has adequate organ function. Exclusion Criteria: * Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of care therapy. * Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion. * Has untreated brain or central nervous system metastases or metastases that have progressed * Has a Grade ≥2 corneal epithelial condition. * Has any active renal condition * Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis. * Has a lung-specific intercurrent clinically significant illness * Has FEV1 \<50% predicted * Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract. * Has a known hypersensitivity to any component of GSK5533524 or its excipients. * Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins. * Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug. * Has received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention. * Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment. * The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes. * Has corrected QT interval by Fridericia formula (QTcF) \>470 msec or QTcF \>480 msec for participants with bundle branch block. * Has a left ventricular ejection fraction (LVEF) \< 50%. * Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.

→

Inclusion Criteria: * Is at least 18 years of age or the legal age of consent * Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory or intolerant to standard therapy, has exhausted all treatment options and is not considered a candidate for definitive radiotherapy. * Has documented disease progression based on radiologic imaging, during or after most recent line of treatment. * Has at least one target lesion per RECIST 1.1. * Has an Eastern Cooperative Oncology Group performance status of 0 or 1 and no deterioration in the 2 weeks before enrollment. * Has adequate organ function. * Has a life expectancy of at least 3 months. Exclusion Criteria: * Has a history of clinically significant or uncontrolled cardiac disease, acute myocardial infarction, congestive heart failure or clinically significant arrhythmia not controlled by Standard of care therapy. * Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion. * Has untreated brain or central nervous system metastases or metastases that have progressed * Has a Grade ≥2 corneal epithelial condition. * Has any active renal condition * Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, or current ILD/pneumonitis. * Has a lung-specific intercurrent clinically significant illness * Has FEV1 \<50% predicted * Has chronic enteritis or inflammatory bowel disease or any history of clinically significant bleeding of gastrointestinal tract or clinically significant obstruction and/or perforation and/or fistulae of GI tract. * Has a known hypersensitivity to any component of GSK5533524 or its excipients. * Has history of severe allergies, or severe infusion related reactions, or idiosyncrasy to recombinant humanized proteins. * Has received any cytotoxic chemotherapy drugs, or other anti-tumor drugs within 28 days prior to the first dose of study drug. * Has received radiotherapy to the lungs, or to adjacent organs, within 6 months prior to the first dose of study intervention; locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study intervention. * Has received immunosuppressive agents or required long-term glucocorticoid therapy within 30 days prior to first dose of study treatment. * The use of concomitant medications known to prolong the QT/QTc interval or potentially cause torsades de pointes. * Has corrected QT interval by Fridericia formula (QTcF) \>470 msec or QTcF \>480 msec for participants with bundle branch block. * Has a left ventricular ejection fraction (LVEF) \< 50%. * Has risk factors for prolonged QT/QTc or TdP, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old.

CTGOV10/6/2026, 5:05:10 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the Informed consent * Elevated Blood Eosinophil Count (BEC) * Moderate to severe COPD with frequent exacerbations, defined as: * A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year * A post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio of \< 0.70 and a post-bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values * A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening * COPD assessment test (CAT) score \>=10 at Visit 1 * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years. * Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1 * Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2) * Male and eligible female participants Exclusion Criteria: The following subjects are excluded: * Participants with a current or prior physician diagnosis of asthma * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1 * Lung resection: Participants with a history of or plan for lung volume reduction surgery / endobronchial valve procedure. * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1 * Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day * Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension * Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \[BiPAP\] or Continuous Positive Airway Pressure \[CPAP\]) * Unstable cardiovascular disease or arrhythmia * Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)

→

Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the Informed consent * Elevated Blood Eosinophil Count (BEC) * Moderate to severe COPD with frequent exacerbations, defined as: * A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year * A post-bronchodilator forced expiratory volume in one second (FEV1)/ forced vital capacity (FVC) ratio of \< 0.70 and a post-bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values * A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening * COPD assessment test (CAT) score \>=10 at Visit 1 * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years. * Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1 * Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2) * Male and eligible female participants Exclusion Criteria: The following subjects are excluded: * Participants with a current or prior physician diagnosis of asthma * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1 * Lung resection: Participants with a history of or plan for lung volume reduction surgery / endobronchial valve procedure. * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1 * Continuous oxygen: Participants requiring oxygen supplementation for more than 16 hours per day to maintain resting oxygen saturation greater than 88% * Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension * Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \[BiPAP\] or Continuous Positive Airway Pressure \[CPAP\]) * Unstable cardiovascular disease or arrhythmia * Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)

CTGOV10/6/2026, 5:05:12 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent. * Elevated blood eosinophil count (BEC). * Moderate to severe COPD with frequent exacerbations, defined as: * A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year * A post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post- bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values * A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening * COPD assessment test (CAT) score \>=10 at Visit 1. * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years. * Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1. * Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2). * Male or eligible female participants. Exclusion Criteria: The following subjects are excluded: * Participants with a current or prior physician diagnosis of asthma. * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease. * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1. * Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure. * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1. * Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day. * Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension * Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \[BiPAP\] or Continuous Positive Airway Pressure \[CPAP\]). * Unstable cardiovascular disease or arrhythmia. * Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1).

→

Inclusion Criteria: * Participants must be greater than or equal to (\>=) 40 to less than or equal to (\<=) 80 years of age, at the time of signing the informed consent * Elevated blood eosinophil count (BEC). * Moderate to severe COPD with frequent exacerbations, defined as: * A clinically documented history of COPD as defined by the American Thoracic Society/European Respiratory Society for at least 1 year * A post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio of less than (\<) 0.70 and a post- bronchodilator FEV1 \>30 percent (%) and \<= 80% predicted normal values * A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening * COPD assessment test (CAT) score \>=10 at Visit 1 * Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years. * Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1 * Body mass index (BMI) \>=16 kilogram per square meter (kg/m\^2). * Male or eligible female participants Exclusion Criteria: The following subjects are excluded: * Participants with a current or prior physician diagnosis of asthma * Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease * Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1 * Lung resection: Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure * Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1. * Continuous oxygen: Participants requiring oxygen supplementation for more than 16 hours per day to maintain resting oxygen saturation greater than 88% * Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension * Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \[BiPAP\] or Continuous Positive Airway Pressure \[CPAP\]) * Unstable cardiovascular disease or arrhythmia. * Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1)

CTGOV10/8/2026, 5:07:49 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: 1. Have a clinical diagnosis of SLE according to the SLICC criteria 2012 2. Severe, active SLE disease defined as a situation in which 1 or more of the following criteria are met: 1. SLEDAI-2K (SLE Disease Activity Index) with 12 or more points 2. New or worse SLE-related activity of major organs, i.e.: CNS-SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia \< 60, hemolytic anemia \< 4.4mmol/L (=7.0g/dL) 3. high disease activity that requires or warrants induction treatment by switching to or increasing dosage of oral mycophenolate 3. New, persisting or progressive disease activity despite the use of conventional maintenance immunosuppressive treatment (e.g. mycophenolate or azathioprine) 4. Positive for relevant SLE-specific autoantibodies defined as a situation in which 1 or more of the following criteria are met: 1. ANA seropositivity, as defined by a positive ANA-titer ≥ 1:80, before and at screening : * Positive test results from 2 independent time points within the study screening period; OR * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of ANA (eg, ANA by HEp-2 titer, ANA by ELISA) must include the date of the test. 2. Anti-DNA seropositivity, as defined by a positive anti-dsDNA serum antibody ≥ 30 IU/mL, before and at screening: * Positive test results from 2 independent time points within the study screening period. * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of anti-dsDNA (eg, anti-dsDNA by Farr assay or ELISA) must include the date of the test. 5. Female subjects are eligible to enter the study if she is: * Not pregnant or nursing * Of non-child-bearing potential (i.e. after hysterectomy, postmenopausal, bilateral ovariectomy or documented bilateral tubal ligation or other permanent female sterilization procedure) * in agreement to not become pregnant (if female subjects of childbearing potential) and therefore must be sexually inactive by abstinence or use contraceptive methods with a failure rate of \< 1%. Exclusion Criteria: 1. Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG 2. Significant hypogammaglobulinemia (IgG \< 4.0 g/L) or an IgA deficiency (IgA \< 0.1 g/L) 3. Immunization with a live vaccine 1 month before screening 4. Active infection at time of screening, as follows: * Hospitalization for treatment of infection within previous 60 days of day 0 of the study * Use of parenteral (intravenous of intramuscular) antibiotics (including anti-bacterials, anti-virals, anti-fungals or anti-parasitic agents) within previous 60 days of day 0 of the study * Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or HBcAb or a positive hepatitis C antibody not treated with antiviral medication 5. Have a historically positive HIV test or test positive at screening for HIV 6. Have a history of a primary immunodeficiency 7. Have a neutrophil count of \< 1.5x10E9/L 8. Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study 9. Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies 10. Have any other clinically significant abnormal laboratory value in the opinion of the investigator 11. Have current drugs or alcohol abuse or dependence within 365 days prior to Day 0 of the study 12. Have an active malignant neoplasm or one in the history of the last 5 years, except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years 13. Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months or who, in the investigator's opinion, poses a significant suicide risk 14. Have any other clinically significant abnormal laboratory value, any intercurrent significant medical or psychiatric illness that in the opinion of the investigator would make the candidate unsuitable for the study

→

Inclusion Criteria: 1. Have a clinical diagnosis of SLE according to the SLICC criteria 2012 2. Severe, active SLE disease defined as a situation in which 1 or more of the following criteria are met: 1. SELENA-SLEDAI (SLE Disease Activity Index) with 12 or more points 2. New or worse SLE-related activity of major organs, i.e.: CNS-SLE (includes NPSLE), vasculitis, nephritis, pericarditis and/or myocarditis, myositis, thrombocytopenia \< 60, hemolytic anemia \< 4.4mmol/L (=7.0g/dL) 3. high disease activity that requires or warrants induction treatment by switching to or increasing dosage of oral mycophenolate 3. New, persisting or progressive disease activity despite the use of conventional maintenance immunosuppressive treatment (e.g. mycophenolate or azathioprine) 4. Positive for relevant SLE-specific autoantibodies defined as a situation in which 1 or more of the following criteria are met: 1. ANA seropositivity, as defined by a positive ANA-titer ≥ 1:80, before and at screening : * Positive test results from 2 independent time points within the study screening period; OR * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of ANA (eg, ANA by HEp-2 titer, ANA by ELISA) must include the date of the test. 2. Anti-DNA seropositivity, as defined by a positive anti-dsDNA serum antibody ≥ 30 IU/mL, before and at screening: * Positive test results from 2 independent time points within the study screening period. * One positive historical test result and 1 positive result during the screening period. Historical documentation of a positive test of anti-dsDNA (eg, anti-dsDNA by Farr assay or ELISA) must include the date of the test. 5. Female subjects are eligible to enter the study if she is: * Not pregnant or nursing * Of non-child-bearing potential (i.e. after hysterectomy, postmenopausal, bilateral ovariectomy or documented bilateral tubal ligation or other permanent female sterilization procedure) * in agreement to not become pregnant (if female subjects of childbearing potential) and therefore must be sexually inactive by abstinence or use contraceptive methods with a failure rate of \< 1%. Exclusion Criteria: 1. Active pregnancy, as proven by a positive urine beta-HCG test or a positive serum beta-HCG 2. Significant hypogammaglobulinemia (IgG \< 4.0 g/L) or an IgA deficiency (IgA \< 0.1 g/L) 3. Immunization with a live vaccine 1 month before screening 4. Active infection at time of screening, as follows: * Hospitalization for treatment of infection within previous 60 days of day 0 of the study * Use of parenteral (intravenous of intramuscular) antibiotics (including anti-bacterials, anti-virals, anti-fungals or anti-parasitic agents) within previous 60 days of day 0 of the study * Serological evidence of viral hepatitis defined as: patients positive for HbsAg test or HBcAb or a positive hepatitis C antibody not treated with antiviral medication 5. Have a historically positive HIV test or test positive at screening for HIV 6. Have a history of a primary immunodeficiency 7. Have a neutrophil count of \< 1.5x10E9/L 8. Have a significant infection history that in the opinion of the investigator would make the candidate unsuitable for the study 9. Have a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies 10. Have any other clinically significant abnormal laboratory value in the opinion of the investigator 11. Have current drugs or alcohol abuse or dependence within 365 days prior to Day 0 of the study 12. Have an active malignant neoplasm or one in the history of the last 5 years, except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years 13. Have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months or who, in the investigator's opinion, poses a significant suicide risk 14. Have any other clinically significant abnormal laboratory value, any intercurrent significant medical or psychiatric illness that in the opinion of the investigator would make the candidate unsuitable for the study

CTGOV10/10/2026, 5:06:40 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: • Is a full-term infant approximately 2 months of age at time of obtaining the informed consent. Exclusion Criteria: * Had prior administration of any pneumococcal vaccine. * Has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used. * Has a known or suspected immunodeficiency or other conditions associated with immunosuppression that may require immunosuppressive drugs. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive. * Has any clinically significant allergic condition or history prior to the first vaccination for primary immunization series. * Has a history of microbiologically proven invasive disease caused by S. pneumoniae. * Has received immunoglobulins. * Has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection. * Has received systemic corticosteroids for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine.

→

Inclusion Criteria: 1. Participant has an LAR who understands study procedures, alternative treatments and risks involved in the study and who voluntarily agrees to participate by giving informed consent. 2. Participant is a full-term (≥37 weeks gestation at birth) infant approximately 2 months of age (42 to 90 days, inclusive) at time of obtaining the informed consent. 3. Participant is healthy based on the clinical judgment of the investigator following review of medical history and physical examination. Exclusion Criteria: 1. Participant had prior administration of any pneumococcal vaccine. 2. Participant has a known or suspected hypersensitivity to AFX3772, PCV13, PCV20 or any components of the formulations used. 3. Participant has a known or suspected immunodeficiency (including autoimmune disease) or other conditions associated with immunosuppression that may require immunosuppressive drugs including but not limited to HIV infection, malignancy or organ or bone marrow transplant. a. In addition, the participant's biological mother has known HIV infection or known to be hepatitis B surface antigen positive. 4. Participant has any clinically significant allergic condition or history (including anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to the first vaccination for primary immunization series. 5. Participant has functional asplenia. 6. Participant has medical history of epilepsy or febrile convulsion. 7. Participant weighed \<2000 g at birth. 8. Participant has known neurological or cognitive behavioral disorders including clinically significant developmental disorder and related disorders. 9. Participant has any active malignancy or history of malignancy. 10. Participant has a history of microbiologically proven invasive disease caused by S. pneumoniae. 11. Participant has cochlear implant or cerebrospinal fluid leakage. 12. Has received other licensed non-live vaccines within the 14 days or a licensed live virus vaccine within the 30 days prior to receipt of study vaccine. 13. Participant has received immunoglobulins. Note: This does not include monoclonal antibodies, such as palivizumab or nirsevimab. 14. Participant has a bleeding diathesis or condition associated with prolonged bleeding that would contraindicate intramuscular injection. 15. Participant has received systemic corticosteroids (equivalent of \>2 mg/kg total daily dose of prednisone or \>20 mg/day for persons weighing \>10 kg) for a period of more than 14 days and has not completed the treatment for at least 30 days before study vaccine. Topical, ophthalmic, and inhaled steroids are allowed. 16. Participant has febrile illness (rectal temperature ≥38.1°C \[100.5°F\] or axillary temperature ≥37.8°C \[100.0°F\]) in Part 1 and Part 2 prior to the effective date of protocol amendment 4. After protocol amendment 4 becomes effective, febrile illness is defined as rectal temperature ≥38.0°C \[100.4°F\] or axillary temperature ≥37.5°C (99.1°F) in Part 2. Upon resolution of symptoms, participant can be rescreened. 17. Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening. 18. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation. 19. LARs that are study personnel or their immediate dependents, family, or household members.

CTGOV10/20/2026, 5:05:02 AM

Trial eligibility change

eligibility_criteria

Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification). All Cohorts * Is willing to use adequate contraception. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has an ECOG performance status of 0 or 1. * Has adequate organ function. Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: * Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease. * Has had any major surgery within 28 days prior to randomization or first dose of study intervention, depending on sub-cohort/cohort assignment * Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. * Has severe, uncontrolled or active cardiovascular disorders. * Has serious or poorly controlled hypertension. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Has evidence of current ILD/non-infectious pneumonitis or a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids Or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy. * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload. * Is pregnant or breastfeeding.

→

Inclusion criteria: Participants are eligible to be included in the study only if all of the following criteria apply: All cohorts * Is at least 18 years of or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification). All Cohorts * Is willing to use adequate contraception. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has an ECOG performance status of 0 or 1. * Has adequate organ function. Exclusion criteria: Participants are excluded from the study if any of the following criteria apply: * Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease. * Has had any major surgery within 28 days prior to randomization or first dose of study intervention, depending on sub-cohort/cohort assignment * Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. * Has severe, uncontrolled or active cardiovascular disorders. * Has serious or poorly controlled hypertension. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Has evidence of current ILD/non-infectious pneumonitis or a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids Or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy. * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload. * Is pregnant or breastfeeding.

CTGOV10/28/2026, 5:04:55 AM

Trial eligibility change

eligibility_criteria

Key Inclusion Criteria: * Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301 * Able to comprehend and willing to sign the informed consent form Key Exclusion Criteria: * Known hypersensitivity to MMB, its metabolites, or formulation excipients NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

→

Inclusion Criteria: * Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301 * Did not discontinue treatment with MMB for any reason while enrolled in Studies GS US 352-0101, GS-US-352-1214, GS-US-352-1154, or SRA-MMB-301 * A negative serum or urine pregnancy test is required for female participants of childbearing potential * Female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception * Any Grade 3 or 4 (common terminology criteria for adverse events \[CTCAE\] Version 4.03) non-hematologic toxicity in the prior study that the Investigator considers related to previous MMB use must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study * Any AE requiring MMB interruption during the prior study must have resolved, reverted to Grade 1, or reverted to Baseline within the 30 days from last MMB administration to Day 1 of this study * Ability and agreement to attend protocol-specified visits at the study site * Able to comprehend and willing to sign the informed consent form Exclusion Criteria: * Known hypersensitivity to MMB, its metabolites, or formulation excipients * Incomplete recovery from major surgery prior to Day 1 of this study * Pregnant or lactating females * Presence of greater than or equal to (\>=) Grade 3 (CTCAE Version 4.03) peripheral neuropathy * Known positive status for human immunodeficiency virus (HIV) * Known chronic active or acute viral hepatitis A, B, or C infection

CTGOV10/29/2026, 5:05:36 AM

Trial eligibility change

eligibility_criteria

Inclusion Criteria: * Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. * Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane based chemotherapy regimens. Exclusion Criteria: * Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma. * Impaired cardiac function or clinically significant cardiac disease. * Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality. * Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.

→

Inclusion Criteria: * Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate. * Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks). * Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use. Exclusion Criteria: * Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma. * Impaired cardiac function or clinically significant cardiac disease. * Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality. * Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.

results_first_posted	null	→	2026-09-21
adverse_events_module_present	false	→	true

primary_outcomes	[object Object]	→	[object Object],[object Object],[object Object]
secondary_outcomes	[object Object],[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object],[object Object]

enrollment_type	ESTIMATED	→	ACTUAL
enrollment_count	62	→	66

primary_outcomes	[object Object],[object Object]	→	[object Object],[object Object]
secondary_outcomes	[object Object],[object Object],[object Object],[object Object]	→	[object Object],[object Object],[object Object],[object Object]

results_first_posted	null	→	2026-09-24
adverse_events_module_present	false	→	true

completion_date	2029-12-21	→	2029-12-24
primary_completion_date	2029-06-21	→	2029-06-22

completion_date	2028-09-29	→	2030-05-01
primary_completion_date	2026-07-13	→	2028-02-14

completion_date	2029-09-01	→	2027-07-29
primary_completion_date	2026-10-21	→	2027-07-29

completion_date	2027-05-13	→	2027-05-17
primary_completion_date	2027-05-05	→	2027-05-17

completion_date	2029-12-19	→	2029-12-05
primary_completion_date	2029-12-19	→	2029-12-05

completion_date	2026-05-25	→	2027-05-14
primary_completion_date	2026-05-25	→	2027-05-14

completion_date	2026-01-31	→	2027-01-31
primary_completion_date	2026-01-31	→	2027-01-31

completion_date	2026-11-24	→	2026-11-17
primary_completion_date	2026-11-24	→	2026-11-17

completion_date	2029-08-21	→	2029-02-14
primary_completion_date	2029-08-21	→	2028-12-13

completion_date	2028-04-19	→	2028-04-10
primary_completion_date	2028-04-19	→	2028-04-10

completion_date	2029-08-20	→	2029-02-14
primary_completion_date	2029-08-20	→	2028-12-13

completion_date	2026-09-22	→	2027-05-20
primary_completion_date	2026-09-22	→	2027-05-20

results_first_posted	null	→	2026-10-06
adverse_events_module_present	false	→	true

completion_date	2026-06-07	→	2026-06-22
primary_completion_date	2024-06-07	→	2026-06-22

results_first_posted	null	→	2026-10-09
adverse_events_module_present	false	→	true

completion_date	2027-11-24	→	2027-10-29
primary_completion_date	2027-11-24	→	2027-10-29

completion_date	2026-06-30	→	2027-12-30
primary_completion_date	2026-06-30	→	2027-08-30

completion_date	2029-04	→	2029-06
primary_completion_date	2029-04	→	2029-06

completion_date	2029-12-17	→	2030-07-22
primary_completion_date	2029-12-17	→	2030-07-22

completion_date	2028-01	→	2029-06-01
primary_completion_date	2027-01-01	→	2028-06-01

completion_date	2026-07-01	→	2026-06-19
primary_completion_date	2026-07-01	→	2026-06-19

completion_date	2029-05-04	→	2029-05-02
primary_completion_date	2029-05-04	→	2029-05-02

completion_date	2026-12-31	→	2027-12-31
primary_completion_date	2025-06-01	→	2027-06-01

results_first_posted	null	→	2026-10-26
adverse_events_module_present	false	→	true

results_first_posted	null	→	2026-10-27
adverse_events_module_present	false	→	true

completion_date	2026-12-09	→	2026-11-19
primary_completion_date	2026-12-09	→	2026-11-19

completion_date	2028-12-04	→	2029-03-21
primary_completion_date	2028-07-31	→	2029-03-21

completion_date	2026-01-31	→	2026-12-24
primary_completion_date	2025-11-30	→	2026-11-30

completion_date	2029-09-24	→	2030-01-10
primary_completion_date	2029-09-24	→	2030-01-10

completion_date	2027-08-31	→	2028-09-30
primary_completion_date	2026-07-15	→	2026-12-14